靶向CD47治疗髓系肿瘤的相关进展

Advances in targeting CD47 in the treatment of myeloid malignancies

CD47作为“don’t eat me”信号在髓系肿瘤表面表达上调,可与巨噬细胞上信号调节蛋白α相结合抑制巨噬细胞吞噬功能,在肿瘤细胞的免疫逃避中起作用。有研究表明,CD47高表达与骨髓增生异常综合征的进展及急性髓系白血病的不良预后相关。CD47作为固有免疫中备受瞩目的免疫检查点,靶向CD47治疗髓系肿瘤的多种药物目前已经进入临床试验阶段,有望成为治疗髓系肿瘤的强有力手段。

As the "don’t eat me" signal,CD47is upregulated on the surface of myeloid malignancies and binds to signal regulatory protein alpha on macrophages to inhibit macrophage phagocytosis,and play a role in the immune evasion of malignancy cells.Studies have shown that high expression of CD47is associated with the progression of myelodysplastic syndrome and poor prognosis in acute myeloid leukemia.CD47is a high-profile immune checkpoint in innate immunity,and a variety of drugs targeting CD47for the treatment of myeloid malignancies have entered the stage of clinical trial.Related drugs are expected to become a powerful means of treating myeloid malignancies.